Unique Considerations in Women with Inflammatory Bowel Disease

Raina Shivashankar*

Department of Medicine and Division of Gastroenterology and Hepatology, Thomas Jefferson University, Philadelphia, PA, USA

*Corresponding author: Raina Shivashankar, Department of Medicine and Division of Gastroenterology and Hepatology, Thomas Jefferson University, 132 South 10th Street, Main Building, Suite 480, Philadelphia, PA 19107, USA

Citation: Shivashankar R (2022) Unique Considerations in Women with Inflammatory Bowel Disease. J Surg 7: 1479 DOI: 10.29011/2575-9760.001479

Received Date: 25 February, 2022; Accepted Date: 07 March, 2022; Published Date: 10 March, 2022

Abstract

The incidence of Inflammatory Bowel Disease (IBD) is increasing globally. Female patients have special considerations such as hormonal fluctuations affecting gastrointestinal symptoms; Oral Contraceptive Pill (OCP) use and effects on IBD development, need for surgery, Venous Thromboembolism (VTE) risk; fertility; and cervical cancer screening. Providers must be aware of these important considerations in female patients, and this review seeks to delineate these important, non-pregnancy related issues.

Epidemiology

Inflammatory Bowel Disease (IBD) is a chronic gastrointestinal inflammatory disease that includes both Crohn’s Disease (CD) and Ulcerative Colitis (UC). The epidemiology of IBD continues to change globally and the rates of IBD have increased with time [1]. The incidence of IBD has increased in developing countries as these regions become more westernized [2]. The cause for this is unclear, however many have hypothesized that sanitation, diet, microbial exposure, and pollution may be involved [2].

A population-based cohort study of Olmsted County, MN residents from 1970-2010 showed the incidence rates for men compared to women are consistently higher across all age groups [3]. There is a divergence at older ages and the reason for this is unclear [3]. On the other hand, the incidence rates of CD is similar in men and women [3]. However, the data have been divergent on rates of CD between males and females. For instance, other studies have found in Europe and the United States, CD prevalence may be higher in females than males [4]. Early-onset CD has been found more frequently in males than in females; older females (ages 25-29 and more so in those over the age of 35) have been more likely to develop CD compared to males [4]. One study estimated a risk of up to 40% [4]. Betteridge, et al. assessed the prevalence of IBD in a military health care population between 2008-2009 and found that IBD was more prevalent in females compared to males (Relative Risk [RR] 1.53; 95% confidence interval (CI), 1.50-1.57) [5,6]. Additionally there was an increased prevalence of IBD seen at older ages.

Hormonal Fluctuations & IBD Symptoms

Women with IBD may report either improved or worsening gastrointestinal symptoms during their menstrual cycle. Rolston, et al. studied the association between hormonal fluctuations and change in IBD symptoms in an online cohort of women using a 5-point Likert scale [7]. Over half of the women in this study had increased symptoms during their menses and there was no significant difference between women with CD and UC [7]. About 30% of this cohort did report extreme change in symptoms at time of hormonal fluctuations [7]. In this study use of HRT and hormonal contraception was not associated with change in IBD symptoms [7]. There was no significant change in IBD symptoms after menopause [7]. Also, interestingly, pregnancy was associated with an improvement in symptoms in a majority of female patients with IBD.

However, the data in the literature about symptom change during menstruation has been variable. Some studies have found higher rates of diarrhea during menses in women with CD than in those with UC, and women with CD were more likely to report worsening symptoms than those with UC [8-10]. There have been a number of proposed mechanisms by which hormonal fluctuation could affect the gastrointestinal tract: prostaglandin production and...
its effect on colonic smooth muscle and estrogen’s effects on gut permeability and motility [7]. However, it is unclear if symptom increase during hormonal fluctuations translates to an increase in IBD-related inflammation [7]. Therefore, if there is an increase in gastrointestinal symptoms, increased inflammatory activity must be confirmed with objective biomarkers or endoscopic/radiographic evaluation before appropriate therapy can be instituted.

**Oral Contraceptive Use and IBD**

Oral contraceptive pills (OCP) are commonly used for contraception. There have been differing data on the relationship between OCP use and the development of IBD. A meta-analysis was completed in 2017 to assess the association between OCP use and risk of IBD [11]. Ortiz et al. found an increased risk of IBD development in patients exposed to OCP compared to those who were not exposed to these medications (odds ratio [OR]: 1.32, 95% CI: 1.17-1.49, p<0.001) [11]. This study found a 24% increased risk of developing CD and a 30% increased risk of developing UC in those exposed to OCP [11]. However, further studies are needed to elucidate the total dose and duration of OCP use and its effect on development of IBD.

Long-term use of OCP may be associated with increased risk of surgery [12]. A prospective study of female CD patients from the Swedish National Patient Register studied this with the primary outcome of interest being first CD-related surgery [12]. They found a higher risk of surgery in current OCP users compared to non-OCP users; the risk of surgery increased with longer term use of OCP [12]. OCP use and active IBD may increase the risk of VTE. The overall risk of VTE in IBD patients is higher than in those without IBD (Hazard Ratio [HR] 3.4, 95% CI 2.7-4.3, p<0.001) [13]. Furthermore, the risk of VTE in an IBD patient who is experiencing a flare is significantly higher (HR 8.4, 95% CI 5.5-12.8, p<0.001) [13]. The risk for VTE in the general population is higher in those with OCP use compared to those without OCP use [14]. Pellino, et al. conducted a retrospective review of an Italian IBD database and compared 146 IBD patients on OCP to 290 non-IBD matched controls [15]. They found no significant difference in the incidence of VTE between IBD patients in remission and in non-IBD patients [15]. In general, there is likely little avoidance of estrogen-based contraception in usual clinical practice [16,17]. However, it may be prudent to avoid estrogen-based oral contraceptives in those with multiple VTE risk factors such as active uncontrolled IBD, current smoking, and history of VTE.

**Fertility and IBD**

Since IBD can affect women of childbearing age, fertility can be a significant issue. Voluntary childlessness is more commonly noted in patients with IBD than in the non-IBD population [18]. Studies have suggested decreased fertility in women with active CD but normal fertility in women with CD in remission and in women with UC [19-21]. Decreased fertility may be related to transtranular inflammation leading to pelvic inflammation, which in turn could affect the ovaries and fallopian tubes, and a decrease in anti-Mullerian hormone [22]. Studies of women with UC who undergo total proctocolectomy with Ileal Pouch Anal Anastomosis (IPAA) have shown a threefold increase in infertility (average infertility rate increased from 15% to 48% post IPAA) [23]. However, the success rates of In Vitro Fertilization (IVF) in women with IPAA are similar to women with UC without an IPAA and to non-IBD patients [24].

A population-based study from Sweden conducted by Druefors, et al. showed that fertility was decreased in women with CD but was almost normal in women with UC [22]. Increased disease severity and number of surgeries was associated with decreased fertility [22]. Active disease and flares may decrease fertility by local inflammation on pelvic organs, malnutrition, and associated depression [22]. Therefore, aggressive treatment to prevent severe, complicated disease requiring surgeries is paramount, and a multidisciplinary approach is the most effective.

**Cervical Cancer Screening**

Health maintenance is an extremely important aspect of the care of patients with IBD. Risk factors associated with increased risk of cervical cancer include smoking and immunosuppression [25]. Some data suggest that women on immunosuppression, such as IBD patients on biologics, thiopurines, or methotrexate, are screened less frequently than what is recommended [25]. Singh et al. conducted a study that showed 54% of women with IBD received cervical cancer screening, however exposure to immunosuppression and having a diagnosis of CD were independent predictors of decreased screening [26]. A meta-analysis by Allegratti, et al. found that there may be an increased risk of cervical high-grade dysplasia and cancer in IBD patients who are on immunosuppression [27]. Given this, the recommendation for cervical cancer screening in IBD patients by the American College of Gastroenterology (ACG) states that “women with IBD on immunosuppressive therapy should undergo annual cervical cancer screening [25].” Notably, both the American College of Obstetricians and Gynecologists (ACOG) and the Centers for Disease Control (CDC) also suggest annual screening for women who are chronically immunosuppressed [25].

**Conclusion**

There are several issues that are unique to women in the medical management of IBD. Hormonal fluctuations may affect gastrointestinal symptoms however it is unclear if this translates to increased disease activity. OCP may be implicated in the development of IBD and there may be an association with CD-related surgeries. However, it is important to be cautious of OCP use in IBD patients who have multiple VTE risk factors. The data is
variable on fertility rates in women with IBD but there is a decrease in fertility rates in those who have undergone an IPAA procedure. Finally, it is important to remember cervical cancer screening in IBD patients especially those who are immunosuppressed. Providers must be cognizant of these special issues when seeing women with IBD.

References

1. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, et al. (2012) Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142: 46-54.
2. Shivashankar R, Lewis JD (2017) The Role of Diet in Inflammatory Bowel Disease. Curr Gastroenterol Rep 19: 22.
3. Shivashankar R, Tremaine WJ, Harmsen WS, Loftus EV (2017) Incidence and Prevalence of Crohn’s Disease and Ulcerative Colitis in Olmsted County, Minnesota From 1970 Through 2010. Clin Gastroenterol Hepatol 15: 857-863.
4. Greuter T, Manser C, Pittet V, Varvicka SR, Biedermann L, et al. (2020) Gender Differences in Inflammatory Bowel Disease. Digestion 1: 98-104.
5. Betteridge JD, Armbruster SP, Maydonovitch C, Veerappan GR (2013) Inflammatory bowel disease prevalence by age, gender, race, and geographic location in the U.S. military health care population. Inflamm Bowel Dis 19: 1421-1427.
6. Task Force M, Ryden L, Grant PJ, Ank er SD, Berne C, et al. (2013) ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34: 3035-3087.
7. Rolston VS, Boroujerdi L, Long MD, McGovern DPB, Chen W, et al. (2018) The Influence of Hormonal Fluctuation on Inflammatory Bowel Disease Symptom Severity-A Cross-Sectional Cohort Study. Inflamm Bowel Dis 24: 387-393.
8. Kane SV, Sable K, Hanauer SB (1998) The menstrual cycle and its effect on inflammatory bowel disease and irritable bowel syndrome: a prevalence study. Am J Gastroenterol 93: 1867-1872.
9. Parlak E, Dagli U, Alkim C, Dişibeyaz S, Tunç B, et al. (2003) Pattern of gastrointestinal and psychosomatic symptoms across the menstrual cycle in women with inflammatory bowel disease. Turk J Gastroenterol 14: 250-256.
10. Bernstein MT, Graff LA, Targownik LE, Downing K, Shafer LA, et al. (2012) Gastrointestinal symptoms before and during menses in women with IBD. Aliment Pharmacol Ther 36: 135-144.
11. Ortiz R, Lee SY, Nguyen ET, Jamal MM, Bechtold MM, et al. (2017) Exposure to oral contraceptives increases the risk for development of inflammatory bowel disease: a meta-analysis of case-controlled and cohort studies. Eur J Gastroenterol Hepatol 29: 1064-1070.
12. Khalili H, Granath F, Smedby KE, Ekblom A, Neovius M, et al. (2016) Association Between Long-term Oral Contraceptive Use and Risk of Crohn’s Disease Complications in a Nationwide Study. Gastroenterology 150: 1561-1567.
13. Grainge MJ, West J, Card TR (2010) Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 375: 657-663.
14. van Hyckama Vlieg A, Helmerhorst FM, Vandenbergroucke JP, Doggen CJM, Rosendaal FR (2009) The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 339: b2921.
15. Pellino G, Sclaudone G, Caprio F, Candillo G, Fatico GS, et al. (2015) Hormonal contraceptives and venous thromboembolism: Are inflammatory bowel disease patients at increased risk? A retrospective study on a prospective database. Ann Med Surg (Lond) 4: 462-466.
16. Cotton CC, Baird D, Sandler RS, et al. (2016) Hormonal Contraception Use is Common Among Patients with Inflammatory Bowel Diseases and an Elevated Risk of Deep Vein Thrombosis. Inflamm Bowel Dis 22: 1631-1638.
17. Nguyen GC, Bernstein CN, Bitton A, Long MD (2014) Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology 146: 835-848.
18. Mountifield R, Bampton P, Prosser R, Muller K, Andrews JM (2009) Fear and fertility in inflammatory bowel disease: a mismatch of perception and reality affects family planning decisions. Inflamm Bowel Dis 15: 720-725.
19. van der Woude CJ, Aridzzone S, Bengtson MB, Fiorino G, Fraser G, et al. (2015) The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis 9: 107-124.
20. Ban L, Tata Li, Humes DJ, Fiaschi L, Card T (2015) Decreased fertility rates in 9639 women diagnosed with inflammatory bowel disease: a United Kingdom population-based cohort study. Aliment Pharmacol Ther 42: 855-866.
21. Hudson M, Flett G, Sinclair TS, Brunt PA, Templeton A, et al. (1997) Fertility and pregnancy in inflammatory bowel disease. Int J Gynaecol Obstet 58: 229-237.
22. Druvefors E, Landerholm K, Hammar U, Myrelid P, Andersson RE, et al. (2021) Impaired Fertility in Women With Inflammatory Bowel Disease: A National Cohort Study From Sweden. J Crohns Colitis 15: 383-390.
23. Waljee A, Waljee J, Morris AM, Higgins PDR (2006) Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut 55: 1575-1580.
24. Pabby V, Oza SS, Dodge LE, Hacker MR, Moragianni VA, et al. (2015) In Vitro Fertilization Is Successful in Women With Ulcerative Colitis and Ileal Pouch Anal Anastomosis. Am J Gastroenterol 110: 792-797.
25. Farraré FA, Melmed GY, Lichtenstein GR, Kane SV (2017) ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol 112: 241-258.
26. Singh H, Nugent Z, Demers AA, Bernstein CN (2011) Screening for cervical and breast cancer among women with inflammatory bowel disease: a population-based study. Inflamm Bowel Dis 17: 1741-1750.
27. Allegretti JR, Barnes EL, Cameron A (2015) Are patients with inflammatory bowel disease on chronic immunosuppressive therapy at increased risk of cervical high-grade dysplasia/cancer? A meta-analysis. Inflamm Bowel Dis 21: 1089-1097.